tiprankstipranks
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
US Market
IDYA
IDEAYA Biosciences
RESEARCH TOOLSreports

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

648 Followers
See the Price Targets and Ratings of:

IDYA Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
IDEAYA
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$54.80
▲(77.29% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $54.80 with a high forecast of $78.00 and a low forecast of $44.00. The average price target represents a 77.29% change from the last price of $30.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","46":"$46","79":"$79","29.5":"$29.5","62.5":"$62.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,29.5,46,62.5,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.48,35.981538461538456,39.48307692307692,42.98461538461538,46.48615384615384,49.987692307692306,53.489230769230765,56.99076923076923,60.49230769230769,63.99384615384615,67.49538461538461,70.99692307692308,74.49846153846153,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.48,34.19692307692307,35.91384615384615,37.630769230769225,39.347692307692306,41.06461538461538,42.78153846153846,44.498461538461534,46.215384615384615,47.93230769230769,49.64923076923077,51.36615384615384,53.083076923076916,{"y":54.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.48,33.36615384615384,34.25230769230769,35.138461538461534,36.02461538461538,36.910769230769226,37.79692307692308,38.683076923076925,39.56923076923077,40.45538461538462,41.34153846153846,42.22769230769231,43.113846153846154,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.31,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$78.00Average Price Target$54.80Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on IDYA
Charles Zhu
LifeSci Capital
LifeSci Capital
$58→$62
Buy
100.58%
Upside
Assigned
04/09/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Jefferies Analyst forecast on IDYA
Maury Raycroft
Jefferies
Jefferies
$31→$52
Buy
68.23%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Wells Fargo Analyst forecast on IDYA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$44
Buy
42.35%
Upside
Reiterated
04/02/26
Wells Fargo Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
Mizuho Securities Analyst forecast on IDYA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$46
Buy
48.82%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and IDEAYA Biosciences (NASDAQ: IDYA)
Wedbush Analyst forecast on IDYA
Robert Driscoll
Wedbush
Wedbush
$52
Buy
68.23%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), PepGen Inc. (NASDAQ: PEPG) and IDEAYA Biosciences (NASDAQ: IDYA)
J.P. Morgan Analyst forecast on IDYA
Anupam Rama
J.P. Morgan
J.P. Morgan
$78
Buy
152.35%
Upside
Reiterated
03/23/26
J.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
Truist Financial Analyst forecast on IDYA
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on IDYA
Paul Jeng
Guggenheim
Guggenheim
$50
Buy
61.76%
Upside
Reiterated
03/22/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Incyte (NASDAQ: INCY)
UBS Analyst forecast on IDYA
Michael Yee
UBS
UBS
$50
Buy
61.76%
Upside
Reiterated
03/22/26
Analysts' Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
Citi Analyst forecast on IDYA
Yigal Nochomovitz
Citi
Citi
$65
Buy
110.29%
Upside
Reiterated
03/06/26
Citi opens 'upside 90-day catalyst watch' on Ideaya BiosciencesCiti opens 'upside 90-day catalyst watch' on Ideaya Biosciences
TD Cowen Analyst forecast on IDYA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/20/26
IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating
RBC Capital Analyst forecast on IDYA
Leonid Timashev
RBC Capital
RBC Capital
$45→$49
Buy
58.52%
Upside
Reiterated
02/17/26
RBC Capital Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
Barclays Analyst forecast on IDYA
Peter Lawson
Barclays
Barclays
$40
Buy
29.41%
Upside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
Oppenheimer Analyst forecast on IDYA
Matthew Biegler
Oppenheimer
Oppenheimer
$36
Buy
16.47%
Upside
Reiterated
11/04/25
Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
BTIG Analyst forecast on IDYA
Justin Zelin
BTIG
BTIG
$62
Buy
100.58%
Upside
Reiterated
11/04/25
IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on IDYA
Charles Zhu
LifeSci Capital
LifeSci Capital
$58→$62
Buy
100.58%
Upside
Assigned
04/09/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Jefferies Analyst forecast on IDYA
Maury Raycroft
Jefferies
Jefferies
$31→$52
Buy
68.23%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Wells Fargo Analyst forecast on IDYA
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$44
Buy
42.35%
Upside
Reiterated
04/02/26
Wells Fargo Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
Mizuho Securities Analyst forecast on IDYA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$46
Buy
48.82%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (NASDAQ: PEPG) and IDEAYA Biosciences (NASDAQ: IDYA)
Wedbush Analyst forecast on IDYA
Robert Driscoll
Wedbush
Wedbush
$52
Buy
68.23%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), PepGen Inc. (NASDAQ: PEPG) and IDEAYA Biosciences (NASDAQ: IDYA)
J.P. Morgan Analyst forecast on IDYA
Anupam Rama
J.P. Morgan
J.P. Morgan
$78
Buy
152.35%
Upside
Reiterated
03/23/26
J.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
Truist Financial Analyst forecast on IDYA
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on IDYA
Paul Jeng
Guggenheim
Guggenheim
$50
Buy
61.76%
Upside
Reiterated
03/22/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Incyte (NASDAQ: INCY)
UBS Analyst forecast on IDYA
Michael Yee
UBS
UBS
$50
Buy
61.76%
Upside
Reiterated
03/22/26
Analysts' Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
Citi Analyst forecast on IDYA
Yigal Nochomovitz
Citi
Citi
$65
Buy
110.29%
Upside
Reiterated
03/06/26
Citi opens 'upside 90-day catalyst watch' on Ideaya BiosciencesCiti opens 'upside 90-day catalyst watch' on Ideaya Biosciences
TD Cowen Analyst forecast on IDYA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/20/26
IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating
RBC Capital Analyst forecast on IDYA
Leonid Timashev
RBC Capital
RBC Capital
$45→$49
Buy
58.52%
Upside
Reiterated
02/17/26
RBC Capital Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
Barclays Analyst forecast on IDYA
Peter Lawson
Barclays
Barclays
$40
Buy
29.41%
Upside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
Oppenheimer Analyst forecast on IDYA
Matthew Biegler
Oppenheimer
Oppenheimer
$36
Buy
16.47%
Upside
Reiterated
11/04/25
Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)
BTIG Analyst forecast on IDYA
Justin Zelin
BTIG
BTIG
$62
Buy
100.58%
Upside
Reiterated
11/04/25
IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

3 Months
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+15.16%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +15.16% per trade.
1 Year
Matthew BieglerOppenheimer
Success Rate
13/17 ratings generated profit
76%
Average Return
+45.31%
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +45.31% per trade.
2 Years
xxx
Success Rate
19/26 ratings generated profit
73%
Average Return
+41.50%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 73.08% of your transactions generating a profit, with an average return of +41.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
20
13
16
21
18
Buy
13
14
12
15
11
Hold
2
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
27
28
36
29
In the current month, IDYA has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 54.80.
Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.99 with a range of -$1.13 to -$0.79. The previous quarter’s EPS was -$0.94. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.
Next quarter’s earnings estimate for IDYA is -$0.99 with a range of -$1.13 to -$0.79. The previous quarter’s EPS was -$0.94. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $5.20M with a range of $0.00 to $21.40M. The previous quarter’s sales results were $10.88M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.
Next quarter’s sales forecast for IDYA is $5.20M with a range of $0.00 to $21.40M. The previous quarter’s sales results were $10.88M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 54.80.
    What is IDYA’s upside potential, based on the analysts’ average price target?
    IDEAYA Biosciences has 77.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IDYA a Buy, Sell or Hold?
          IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is IDEAYA Biosciences’s price target?
            The average price target for IDEAYA Biosciences is 54.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $78.00 ,the lowest forecast is $44.00. The average price target represents 77.29% Increase from the current price of $30.91.
              What do analysts say about IDEAYA Biosciences?
              IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of IDYA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.